Minimizing Disease Activity in Psoriatic Arthritis

The use of objective, validated outcome measures to track progress in symptom control for patients with psoriatic arthritis was discussed in a session at the 2019 ACR/ARP Annual Meeting titled Optimizing Outcomes in Psoriatic Arthritis: A Domain-Based Strategy. In the years since this presentation, additional research has helped supply greater insights into this topic and... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions PsA Resource Center Psoriatic Arthritis tapering Source Type: research

Related Links:

NEW YORK (Reuters Health)—In patients with psoriatic arthritis (PsA) who are resistant to tumor necrosis factor inhibitors (TNFi), guselkumab was more effective than placebo in a phase 3b trial. “Guselkumab is a relatively new treatment and is the first drug in its class (IL-23 inhibitor) to gain approval for PsA,” Dr. Laura Coates of the... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions Source Type: research
SPRING HOUSE, PENNSYLVANIA, December 3, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced new TREMFYA® (guselkumab) efficacy and safety data from the Phase 3b COSMOS trial published in Annals of the Rheumatic Diseases (ARD), evaluating this selective interleukin (IL)-23 inhibitor in adults with active psoriatic arthritis (PsA) who demonstrated inadequate efficacy or intolerance to tumor necrosis factor inhibition (TNFi).1 Results showed significantly higher proportions of patients treated with TREMFYA had improvement in joint signs and symptoms and complete skin clearance versus ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
ConclusionsAbout three quarters of Chinese rheumatologists are familiar with the elements in PsA diagnosis and have good practice habits in diagnosing PsA. Four main challenges in making PsA diagnosis are revealed. There was no significant difference in the knowledge of PsA between WM- and TCM-rheumatologists.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Two experts described the measurements of disease activity used in axial spondyloarthritis and psoriatic arthritis and how rheumatologists can apply them in practice.
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: ACR Convergence Conditions Meeting Reports Spondyloarthritis ACR Convergence 2021 AS Resource Center axial spondyloarthritis (SpA) PsA PsA Resource Center Psoriatic Arthritis Source Type: research
COSMOS trial results in patients with psoriatic arthritis fit with the expectation that"people who've previously failed a TNF inhibitor might be a little less likely to respond to guselkumab."Medscape Medical News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Rheumatology News Source Type: news
J Rheumatol. 2021 Dec;48(12):1892. doi: 10.3899/jrheum.200453.C1.NO ABSTRACTPMID:34853165 | DOI:10.3899/jrheum.200453.C1
Source: J Rheumatol - Category: Rheumatology Authors: Source Type: research
CONCLUSION: Patients who had self-reported elevated spine symptoms, with or without physician-diagnosed axPsA, had worse quality of life and higher disease activity overall than patients without axial manifestations, suggesting an unmet need in this patient population.PMID:34853090 | DOI:10.3899/jrheum.210662
Source: J Rheumatol - Category: Rheumatology Authors: Source Type: research
J Rheumatol. 2021 Dec;48(12):1892. doi: 10.3899/jrheum.200453.C1.NO ABSTRACTPMID:34853165 | DOI:10.3899/jrheum.200453.C1
Source: Journal of Rheumatology - Category: Rheumatology Authors: Source Type: research
CONCLUSION: Patients who had self-reported elevated spine symptoms, with or without physician-diagnosed axPsA, had worse quality of life and higher disease activity overall than patients without axial manifestations, suggesting an unmet need in this patient population.PMID:34853090 | DOI:10.3899/jrheum.210662
Source: Journal of Rheumatology - Category: Rheumatology Authors: Source Type: research
Med Sci Monit. 2021 Dec 2;27:e934927. doi: 10.12659/MSM.934927.ABSTRACTBACKGROUND Psoriasis is a chronic, immune-mediated and hyperproliferative skin disease with both genetic and environmental components. Copy number variations (CNV) of IL22 and LCE3C-LCE3B deletion have been confirmed to be predisposed to psoriasis vulgaris (PsV) in several ethnic groups. However, it remains to be clarified whether CNVs of IL22 and LCE3C are associated with different subtypes of psoriasis (psoriatic arthritis, PsA; erythrodermic psoriasis, EP; and generalized pustular psoriasis, GPP). MATERIAL AND METHODS We enrolled 897 Han Chinese indi...
Source: Medical Science Monitor - Category: Research Authors: Source Type: research
More News: Arthritis | Psoriatic Arthritis | Rheumatology